Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | GFER | P55789 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL839105 | 0.84 | CYP2A13 (0.47) | ALDH1A1HTTSMN1; SMN2HRH3GRIN2B | |
| SCHEMBL840171 | 0.84 | KDM4E (0.54) | ALDH1A1KDM4E | |
| SCHEMBL839698 | 0.83 | KMT2A (0.43) | ALDH1A1KDM4ECYP2C19CYP1A2 | |
| SCHEMBL839362 | 0.81 | ADORA2A (0.36) | ALDH1A1HTTCYP2C19CYP2D6 | |
| SCHEMBL840714 | 0.81 | PDE2A (0.38) | ALDH1A1KDM4EHRH3 | |
| SCHEMBL839176 | 0.80 | ALDH1A1 (0.50) | ALDH1A1KDM4ESMN1; SMN2HRH3CYP2C19 | |
| SCHEMBL840943 | 0.80 | HDAC4 (0.34) | — | |
| SCHEMBL19634167 | 0.78 | ALDH1A1 (0.45) | ALDH1A1HTTKDM4ESMN1; SMN2HRH3 | |
| SCHEMBL2476534 | 0.78 | TRPV3 (0.44) | ALDH1A1KDM4E | |
| SCHEMBL19633984 | 0.75 | ALDH1A1 (0.42) | ALDH1A1HTTKDM4ESMN1; SMN2HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8143246-B2 | 1-(4-(pyridin-2-yl)benzyl)imidazolidine-2,4-dione derivatives | MSD OSS B.V. (NL) | 2012-03-27 | — | — | US | disclosed |
| US-20100144724-A1 | 1-(4-(PYRIDIN-2-YL)BENZYL)IMIDAZOLIDINE-2,4-DIONE DERIVATIVES | N.V.ORGANON | 2010-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144724-A1 | 1-(4-(PYRIDIN-2-YL)BENZYL)IMIDAZOLIDINE-2,4-DIONE DERIVATIVES | OPRD1, CNR1, CNR2 | ALDH1A1 3782/4885HTT 2261/4885KDM4E 2573/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.